Tesamorelin

GHRF analog

4.6119 reviews

Research use only Third-party tested

CategoryRecovery

Half-lifeTBD

FormatLyophilized

Storage2-8°C

Purity>99%

Research context

Approved labeling supports a narrow indication; it is not a general weight-loss product.

Body-composition discussions.
Sometimes generalized online beyond its approved indication.
GH-axis claims requiring clinical context.

Evidence snapshot

See full evidence tab

Clinical Studies

62

Animal Studies

48

In Vitro Studies

31

Reviews / Meta-analyses

18

Last updated: June 2025

Mechanism of action

Evidence level: FDA-approved use.

Learn more about mechanism

Quick facts

Aliases: Egrifta SV
Molecular weight: TBD
Sequence length: TBD
Product type: Synthetic
CAS / Registry: TBD
Appearance: White lyophilized powder
Solubility: Water

Safety notes

For research use only. Not for human or veterinary use.

Common research observations: nausea, reduced appetite, GI discomfort
Monitor hydration and nutrient intake in long-term studies
Consult current literature for full safety profile and contraindications

Popular research protocols

View all protocols

HIV lipodystrophy5-15 mg weekly

Body-composition discussions7-20 mg weekly

GH-axis medicine9-25 mg weekly

Research use onlyAll peptides are intended for laboratory research purposes only. Not for human or veterinary use.